


ABSTRACT



Provided in the present invention is a compound as a PRMT5-MTA inhibitor, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer or a stereoisomer thereof. Further provided in the present invention are a pharmaceutical composition containing the compound and the use thereof in the treatment of cancers.

No Figure